Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Estimated from 3 chart positions in 3 markets.
By chart position
- 🇨🇦CA · Life Sciences#7430K to 100K
- 🇩🇰DK · Life Sciences#933K to 10K
- 🇿🇦ZA · Life Sciences#146500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
17K to 57K🎙 Weekly cadence·35 episodes·Last published 4mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
34K to 113K🇨🇦88%🇩🇰9%🇿🇦3% - Active Followers
Loyal subscribers who consistently listen
13K to 45K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Episode 66: Mark Abelson, Founder of Ora Clinical
Dec 16, 2025
Unknown duration
Episode 62: Ken Suzuki, Chief Marketing Officer at Nautilus Biotechnology
Oct 22, 2025
Unknown duration
Episode 61: Woody Bryan, President and CEO of Revolo Biotherapeutics
Oct 1, 2025
Unknown duration
Episode 60: Part Two: Yochi Slonim, Co-Founder and CEO at Anima Biotech
Sep 17, 2025
Unknown duration
Episode 59, Part One: Yochi Slonim, Co-Founder and CEO at Anima Biotech
Sep 3, 2025
Unknown duration
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 12/16/25 |  Episode 66: Mark Abelson, Founder of Ora Clinical | Are clinical trial protocols a true art form? Find out in a new episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes guest Mark Ableson, founder of Ora Clinical and CRO pioneer. We'll be discussing exploratory endpoints, what to learn from failed trails, and essential factors in choosing a clinical site location. Listen today! | — | ||||||
| 10/22/25 | Episode 62: Ken Suzuki, Chief Marketing Officer at Nautilus Biotechnology | When is the right time for a biotech to bring in a Chief Marketing Officer/CMO? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Ken Suzuki, Chief Marketing Officer at Nautilus Biotechnology. Listen in as we access the marketer inside each of us, discuss how knowing people might be more important than business and finance, and follow the steps to maintain the fine balance between marketing and reality. Let's start the podcast! | — | ||||||
| 10/1/25 | Episode 61: Woody Bryan, President and CEO of Revolo Biotherapeutics | Why is a feather-light touch important in fighting infections? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Woody Bryan, President and CEO of Revolo Biotherapeutics. Tune in as we press the reset button on the human immune system, explore upstream and downstream levers for treating autoimmune diseases, and how to stay competitive in the biotech industry. Let's start the podcast! | — | ||||||
| 9/17/25 | Episode 60: Part Two: Yochi Slonim, Co-Founder and CEO at Anima Biotech | Can AI see and talk to human cells? Find out in today's episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes Yochi Slonim, Co-Founder and CEO at Anima Biotech, to the podcast. Get ready for part two of this special two-part episode as we touch on smarter LLMs, evolved AI agents, and connecting data to real-world biology. Okay, let's start the podcast! | — | ||||||
| 9/3/25 | Episode 59, Part One: Yochi Slonim, Co-Founder and CEO at Anima Biotech | What do software bugs and human cells have in common? Find out in today's episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes Yochi Slonim, Co-Founder and CEO at Anima Biotech, to the podcast. Tune in to part one of this special two-part episode as we double-click on #AIagents, building neural networks, and syncing visual biology with real-world biology. Okay, let's start the podcast! | — | ||||||
| 8/14/25 | Episode 58: Jerry McLaughlin, CEO and Board Member at Life Biosciences | How does a biopharma background prepare you for the biotech playground? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Jerry McLaughlin, CEO and Board Member at Life Biosciences, for an insightful discussion on cellular rejuvenation, working hand in hand with a board of directors, and knowing when to walk away from a clinical trial. Tune in today! | — | ||||||
| 7/22/25 | Episode 57: Jim Brown, DVM, President and CEO of DURECT Corporation | Is the epigenome the "software" of the cell nucleus? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Jim Brown, President and CEO of DURECT Corporation, for a conversation on the importance of a pharmacoeconomic strategy, developing new treatments for alcohol associated hepatitis, and moving beyond what a single individual can do in clinical research. Tune in today! | — | ||||||
| 7/15/25 | Episode 56, Part Two: Michael Tolentino, MD, Co-Founder and Head Scientific Consultant, Aviceda Therapeutics | How do experienced troubleshooters solve a difficult problem? By asking the right questions first! Welcome back to part two of our conversation with Michael Tolentino, MD, Co-Founder and Head Scientific Consultant at Aviceda Therapeutics. Join host Chris O'Brien as he and Dr. Tolentino, explore the traits of top problem solvers, the power of communication, and how silos and "bad apples" can undermine today's biotechs. Okay, let's start the podcast! | — | ||||||
| 7/9/25 | Episode 55: Julio G. Martinez-Clark, CEO and Co-Founder at bioaccess® | How much do you know about clinical trials in Latin America? Take a deep dive with us as we explore the benefits and risks of running studies in this region. In our latest episode of the Biorasi Few & Far Between podcast, host Chris O'Brien welcomes Julio G. Martinez-Clark, CEO and Co-Founder at bioaccess®. Tune in as we spotlight the advantages of running studies in #LATAM - from data quality to speed to approval. | — | ||||||
| 5/28/25 | Episode 54, Part One: Michael Tolentino, MD, Co-Founder and Head Scientific Consultant, Aviceda Therapeutics | The challenge? Decoding the human immune system. Get ready to meet the top challenger on today's episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes Michael Tolentino, MD, Co-Founder and Head Scientific Consultant at Aviceda Therapeutics, to the podcast. Tune in to part one of this special two-part episode as we explore Michael's start in ophthalmology, groundbreaking treatments in intra-retinal therapy, and the importance of being a great communicator. Okay, let's start the podcast! | — | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 4/29/25 | Episode 53: Frank David, Founder and Managing Director, Pharmagellan | How do mission, vision, and data analysis fit into today's biotech goals? Host Chris O'Brien welcomes Frank David, Founder and Managing Director of Pharmagellan to the podcast. Tune in as we explore R&D strategy, de-risking tactics, and how to think about valuation. Listen in to the latest episode of the Biorasi Few & Far Between podcast today! | — | ||||||
| 4/23/25 | Episode 52: Joshua Kresh, Emily Michiko Morris, and Mark Schultz, IPPI | How does a biotech balance great science with IP security to tell their story? Find out on today's episode of the Few & Far Between podcast! Host Chris O'Brien welcomes Joshua Kresh, Emily Michiko Morris, and Mark Schultz from IPPI: The Intellectual Property Policy Institute. Tune in for a fascinating discussion on the dos and don'ts of IP protection. Listen to the latest episode today! | — | ||||||
| 4/3/25 | Episode 51: Dan Oliver, CEO and Founder, Rejuvenate Bio | How do you turn back the epigenetic clock for humans and their animal companions? Host Chris O'Brien welcomes Dan Oliver, CEO and Founder of Rejuvenate Bio, to the podcast. Tune in as we take a deep dive into parallel clinical trials designed to address chronic, age-related diseases in people and their pets. Plus, we'll zoom in on the right corporate structure for biotech products and the benefits of brainstorming. Listen in to the latest episode of the Few & Far Between podcast today! | — | ||||||
| 3/18/25 | Epsiode 50: Jonathan Rigby, Chairman and CEO, Sernova | Now on the Few & Far Between podcast: Did you know that one in ten people with Type 1 Diabetes (TD1) die from hypoglycemia? Today's guest, who has TD1, explains how he turned his passion for helping others into innovative treatments for diabetes and other chronic diseases. Host Chris O'Brien welcomes Jonathan Rigby, Chairman and CEO at Sernova, to the podcast. Listen in as we spotlight Jonathan's 30-year industry journey, the development of implantable bio-hybrid organs, and how to plan for your first 30 days in a new biotech role. Tune in today! | — | ||||||
| 2/27/25 | Episode 49: Eileen Faucher, Principal and Founder, Brass Tacks Health | Today on the Biorasi Few & Far Between podcast: What if you could read a story before its official release? Competitive intelligence gives you early access to information on emerging trends in clinical trials. On today's episode, host Chris O'Brien welcomes Eileen Faucher. Eileen is the Principal and Founder of Brass Tacks Health, a company that provides insights that biotechs need to drive clinically-meaningful therapies. Listen in to get the ROI on competitive intelligence, concise communications, and helping patients find relevant clinical trials. Thanks for listening! | — | ||||||
| 2/18/25 | Episode 48: John Celebi, President and CEO, Sensei Bio | "You have to have the right people, the right team, and good science." - John Celebi, President and CEO, Sensei Bio Welcome back to Biorasi's Few & Far Between podcast. On today's episode, host Chris O'Brien welcomes John Celebi to the pocast. Be sure to tune in for insights into assembling a core management team and how to build openness and inclusivity into biotech company culture. Thank's for listening! | — | ||||||
| 1/15/25 | Episode 46: Ben Olds and Amy Fenollosa, Haven Human Asset Ventures | "There's that old saying, 'culture is how people behave when nobody's looking.' So, if you want to be effective, your [mission and value statements] have to be specific enough to actually guide behavior." - Ben Olds, Executive Coach and Managing Partner, Haven Human Asset Ventures Welcome back to Biorasi's Few & Far Between podcast. On today's episode, host Chris O'Brien welcomes Ben Olds and Amy Fenollosa from Haven Human Asset Ventures. Tune in for an in-depth discussion on the challenges CEOs and other biotech leaders face in building a successful company culture - from guiding behavior to creating safe spaces for innovative ideas. Looking for more information? Be sure to check out the following titles recommended by Ben and Amy in this episode: "Thanks for the Feedback: The Science and Art of Receiving Feedback Well," by Douglas Stone and Sheila Heen "Right Kind of Wrong: The Science of Failing Well," by Amy Edmondson | — | ||||||
| 12/31/24 | Episode 47 - Marc Lajoie, CEO at Outpace Bio | "If you bring powerful technology to a problem that is well understood, then you can really make a difference." - Marc Lajoie, CEO at Outpace Bio Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Marc Lajoie, as they discuss how de novo proteins can be used to reprogram immune cells. Tune in today! | — | ||||||
| 12/12/24 | Episode 46: Dr. Carsten Rudolph, CEO and Managing Director at Ethris | "It's really a very important challenge we had from the very beginning, to see how to stabilize nanoparticles with the messenger RNA so they are not destroyed during nebulization." - Dr. Carsten Rudolph, CEO and Managing Director at Ethris Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Dr. Carsten Rudolph, as they discuss the current state and bright future of nasal vaccine technology. Tune in today! | — | ||||||
| 10/23/24 | Episode 44: Jonathan Scheiman, PhD, Co-Founder and CEO at FitBiomics | "We don't endeavor to make elite athletes better. We endeavor to make society healthier." - Jonathan Scheiman, PhD, Co-Founder and CEO at FitBiomics Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Jonathan Scheiman, as they discuss microbiome solutions for next generation health and longevity. Tune in today! | — | ||||||
| 9/12/24 | Episode 43: Isaac Stoner, Co-founder and CEO at Octagon Therapeutics | "I hope we're moving into the age of the generalist, where knowing how to learn and learning how to learn are more important than specialized knowledge." - Isaac Stoner, Co-founder and CEO at Octagon Therapeutics Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Isaac Stoner, as they discuss immunology, how to build a company, and financing in the biotech world. Tune in today! | — | ||||||
| 7/16/24 | Episode 42: Diana Azzam, PhD, Assistant Professor at Florida International University, Co-Founder at First Ascent Biomedical | “Our studies are open for those that have exhausted standard of care, and we're showing improved responses, and the data is promising. So, I really hope that as we scale up and generate more data, we can actually move to newly diagnosed patients.” - Diana Azzam, PhD, Assistant Professor at Florida International University, Co-Founder at First Ascent Biomedical Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Diana Azzam, as they discuss technological innovations in guiding individualized patient treatments. Tune in today! | — | ||||||
| 5/23/24 | Episode 41: Craig Serra, Head of Clinical Research Scientific and Technical Engagement, Flatiron Health | "It's amazing how many companies there are and how many opportunities for a kind of a match between a human that needs some help and a company that can help." - Craig Serra, Head of Clinical Research Scientific and Technical Engagement, Flatiron Health Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Craig Serra, as they discuss improving and extending the life of every person with cancer and learning from those experiences. Tune in today! | — | ||||||
| 4/25/24 | Episode 40: Professor Justin Stebbing, Editor-in-Chief, Oncogene journal | "I learned very early on that the stupidest cancer cell was cleverer than the cleverest oncologist." - Justin Stebbing, Editor-in-Chief of Oncogene, previously the UK's first NIHR Research Translational Professor of Oncology, Professor of Biomedical Sciences, Anglia Ruskin University, Cambridge. Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Professor Justin Stebbing, as they discuss insights into oncology, knowledge sharing, and the virtuous circle of translational research. Tune in today! | — | ||||||
| 3/26/24 | Episode 39: Dr. Keith Flaherty, Director of Clinical Research at Massachusetts General Hospital Cancer Center | "Technologies have changed enormously in terms of how we can basically procure, preserve, and then interrogate a tumor specimen...like effectively in real time, like a living cancer specimen." - Dr. Keith Flaherty, Director of Clinical Research at Massachusetts General Hospital Cancer Center, Professor of Medicine at Harvard Medical School, and Associate Physician of Hematology and Oncology at Mass. General Hospital. Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and Dr. Keith Flaherty, Director of Clinical Research at Massachusetts General Hospital Cancer Center, as they discuss insights into new therapeutic interventions for oncology patients. Tune in today! | — | ||||||
Showing 25 of 28
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
3 placements across 3 markets.
Chart Positions
3 placements across 3 markets.